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Abstract
Background The prediction of clinical behaviour of breast ductal carcinoma in situ (DCIS) and its progression to invasive 
disease remains a challenge. Alterations of DNA damage repair mechanisms are associated with invasive breast cancer (BC). 
This study aims to assess the role of base excision repair (BER) DNA Polymerase Beta (POLβ) in DCIS.
Methods A cohort of DCIS comprising pure DCIS (n = 776) and DCIS coexisting with invasive BC (n = 239) were prepared 
as tissue microarrays. POLβ protein expression was assessed using immunohistochemistry and correlated with clinicopatho-
logical parameters and patient outcome. Preclinically, we investigated the impact of POLβ depletion on stem cell markers 
in representative DCIS cell line models.
Results Reduced POLβ expression was associated with aggressive DCIS features including high nuclear grade, comedo 
necrosis, larger tumour size, hormonal receptor negativity, HER2 overexpression and high Ki67 index. Combined low 
nuclear/low cytoplasmic POLβ expression showed the strongest association with the features’ characteristics of aggres-
sive behaviour. There was a gradual reduction in the POLβ expression from normal breast tissue, to DCIS, with the lowest 
expression observed in the invasive BC. Low POLβ expression was an independent predictor of recurrence in DCIS patients 
treated with breast conserving surgery (BCS). POLβ knockdown was associated with a significant increase in cell stemness 
markers including SOX2, NANOG and OCT4 levels in MCF10-DCIS cell lines.
Conclusion Loss of POLβ in DCIS is associated with aggressive behaviour and it can predict recurrence. POLβ expression 
in DCIS provides an additional feature for patients’ risk stratification for personalised therapy.
Keywords DCIS · Breast cancer · POLβ · DNA damage response · Prognosis
Introduction
Breast cancer (BC) carcinogenesis is a multistep process that 
involves genetic and epigenetic changes which leads to grad-
ually develops invasive breast cancer (IBC). This multistep 
process transforms normal ductal cells pre-invasive lesions 
and eventually into invasive disease [1]. In breast ductal 
carcinoma in situ (DCIS) the malignant epithelial cells are 
morphologically and genetically similar to their invasive BC 
counterparts, but they are confined within the mammary duct 
system. Prediction of DCIS progression to invasive disease 
or recurrence after initial excision remains a challenge [2].
The maintenance of genomic integrity is achieved by 
DNA protection from damage that could be induced by 
endogenous or exogenous factors [3]. DNA damage repair 
(DDR) is a complex mechanism and depends on the inter-
action between the various pathways [4]. Carcinogenesis is 
driven by impaired DNA repair [5–7]. DNA polymerase β 
(POLβ) is one of the DNA polymerase groups that appear 
to have paramount significance in genome integrity preser-
vation [8–10]. Bases that have been damaged by oxidation, 
alkylation or ring saturation must be removed accurately 
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by the base excision repair (BER) pathway [11]. POLβ is 
recruited to the impaired cells by cooperating with the BER 
scaffold protein (XRCC1) and the DNA damage repair 
protein (PARP1) [12–14]. POLβ is localised on chromo-
some 8p11 and it is a hot spot for chromosomal deletion 
and alterations associated with different types of cancers 
including BC [15–19]. Mutation in POLβ raises the mutation 
frequency which promotes carcinogenesis [20–22].
In this study, we hypothesised that POLβ provides prog-
nostic and predictive value in DCIS. We utilised a large 
well-characterised cohort of DCIS to assess the clinical and 
molecular significance of POLβ expression in DCIS and 
determine its association with the disease progression.
Materials and methods
Study cohort
This retrospective study was carried out on a successive 
series of 1015 DCIS cases comprising pure DCIS (n = 776) 
and DCIS with synchronous invasive BC (DCIS mixed; 
n = 239) diagnosed and treated at the Breast Institute, City 
Hospital, Nottingham, United Kingdom. The demographic 
and histopathological data including age at diagnosis, mode 
of disease presentation (symptomatic or screen-detected), 
DCIS size, nuclear grade, the presence of necrosis and 
postoperative radiotherapy (RT), were collected. Molecular 
classification based on the expression of hormonal recep-
tors [oestrogen and progesterone receptor (ER&PR)], HER2 
status and Ki-67 proliferation index were available as previ-
ously described [23]. ER&PR positivity was defined when 
the positive nuclei of tumour cells were ≥ 1% [24]. Herceptin 
test method was used to assess HER2 where IHC score of 
0 or 1 considered as negative, 2 + considered as equivocal 
and 3 + considered as positive [25]. Moreover, the Ki-67 
proliferation index was defined as high if its nuclear expres-
sion in malignant epithelial cells was more than 14% [23] 
(Supplementary Table S1). Local recurrence-free interval 
(LRFI) was defined as the time between the primary surgical 
excision to the time of development ipsilateral recurrence as 
DCIS or invasive BC. Cases with contralateral breast cancer 
were censored at the time of development of the contralat-
eral event.
Analysis of POLβ mRNA in invasive BC
Due to the limited availability of transcriptomic data of the 
DCIS, the Molecular Taxonomy of Breast Cancer Interna-
tional Consortium (METABRIC) (n = 1980) data were used 
to validate the clinical and prognostic significance of POLβ 
in invasive BC [26].
Evaluation of POLβ protein expression
Western blotting was performed to validate the anti-POLβ 
antibody specificity (Abcam; rabbit polyclonal ab26343. 
Lot No. GR 284,224–3). A panel of human cell lysates was 
used including MCF10DCIS, MCF7, MCF10A and MDA-
MB-231. They were purchased from the American Type 
Culture Collection (Rockville, MD, USA). A single specific 
band at the predicted size of 38 kDa was achieved using an 
antibody dilution at 1:1000 and incubated overnight at 4 °C. 
Anti-beta tubulin (mouse monoclonal anti-beta tubulin anti-
body Abcam) 55 kDa was included in the Western Blot as a 
loading control (Fig. 1A).
The assessment of the expression of POLβ protein in 
DCIS by immunohistochemistry (IHC) was conducted on 
4 µm tissue microarray sections (TMA) and full-face tis-
sue Sects. (10 cases) of formalin-fixed paraffin-embedded 
(FFPE) blocks using the Novocastra Novolink polymer 
detection system (Leica, Newcastle, UK) following the 
manufacturer’s guidelines. Subsequently, samples were 
incubated for 30 min at room temperature with the POLβ 
primary antibody optimally diluted in 1:500 in the Leica 
antibody diluent (Supplementary material and method S1, 
S2).
The scoring, based on a semi-quantitative histochemi-
cal assessment scoring method (H-Score), was conducted 
on POLβ nuclear and cytoplasmic expression. H-score took 
into consideration the staining intensity (negative, weak, 
moderate and strong expression as 0, 1, 2 and 3, respec-
tively) and the percentage of the stained tumour cells. The 
result of scoring was gained by multiplying the intensity of 
staining by the percentage of expression in the nucleus and 
cytoplasm of the tumour cells. The score was expressed in 
a range of 0–300 [27]. All cores with less than 15% tumour 
were excluded from scoring. DCIS component and inva-
sive component in DCIS mixed with invasive were scored 
separately. Moreover, whenever present in the tissue cores, 
expression of POLβ within the adjacent normal terminal 
ductal lobular unit (TDLUs) was also assessed (n = 50). 
X-tile (X-tile Bioinformatics software, Yale University, 
version 3.6.1) was used to dichotomise the nuclear POLβ 
expression into high (H-score > 130) and low, and cytoplas-
mic expression into high (H-score > 60) and low according 
to patient outcome in the pure DCIS cohort [28, 29]. Scor-
ing has been done blindly to clinicopathological data and 
patient outcome. Approximately 30% of cases were double 
scored by another pathologist and the discrepant cases were 
reviewed by both observers and a final score was agreed.
Breast Cancer Research and Treatment 
1 3
POLβ siRNA knockdown (KD) in DCIS cells
MCF10DCIS cells were a gift from prof. Vimla band labora-
tory. MCF10DCIS BC cell line was previously derived from 
a xenograft originating from premalignant MCF10AT cells 
injected into SCID mice [30]. Injection of the MCF10DCIS 
cells into SCID mice results in a predominantly comedo 
DCIS phenotype [30, 31]. MCF10A, MCF-7 and MDA 
-MB231 breast cancer cell lines were purchased from 
ATCC. MCF10DCIS and MCF10A cell lines were cul-
tured in DMEM-F12 supplemented with 10% horse serum, 
5 mg/ml insulin, 1 mg/ml cholera toxin, and 100 μg/mL 
EGFR, 5 mg/mL hydrocortisone and 1% penicillin–strep-
tomycin. MDA-MB231 and MCF-7 cells were cultured in 
minimum essential amino acids medium supplemented with 
10% FBS, 1% penicillin–streptomycin, 1% l-glutamine and 
1% nonessential amino acids. POLβ siRNA were obtained 
from Invitrogen, UK (catalogue no. 4390824, ID: S10776). 
Briefly, 1 ×  106 Cells were seeded in T25 cell culture flasks 
overnight. siRNA constructs were transfected using Lipo-
fectamine 3000 reagent (Invitrogen, UK) (catalogue no. 
L3000001) as per the manufacturer’s protocol in Opti-MEM 
low serum medium (catalogue no. 11058021). Transfection 
efficiency was confirmed on day 3, day 5 and day 7 using 
Fig. 1  POL-β Western blot and IHC protein expression. A West-
ern blot for POL-β antibody showed a single band at the predicted 
molecular weight 38 kDa in the cell lysates MCF7, MCF10A, MDA-
MB231 and MCF10-DCIS, respectively (green bands). Tubulin used 
as an internal loading control and shows a single band as a standard 
control (red band) at the predicted molecular weight 55 kDa in all cell 
lysates. W.B chart was presented the higher level of POL-β protein 
was expressed in MCF10A, MCF7, MCF10DCIS, and MDA-MB 
231, respectively. B–F POL-β protein expression in DCIS. B Normal 
terminal ductal lobular units, lined by single layer of epithelial cells 
(X10). C Negative IHC expression (X20). D Strong IHC expression 
in DCIS (X20). E Weak to moderate IHC expression in IBC compo-
nent (X20). F Mixed DCIS coexistent with IBC (X10)
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western blotting. Evaluation of N-cadherin, C-MYC, OCT4, 
NANOG, SOX2, MMP-9 and ALDH1 protein expression 
was performed by western blotting on extracts of MCF10D-
CIS POLβ control and MCF10-DCIS POLβ_KD.
Statistical analysis
Statistical analysis was conducted using SPSS software 
version 24 (Chicago, IL, USA). Relevant statistical analy-
ses have been carried out based on the distribution of data 
(parametric or non-parametric). Association between POLβ 
mRNA expression with clinicopathological parameters and 
outcome was carried out in the METABRIC database. Chi 
Square, Mann–Whitney and Kruskal Wallis tests were used 
to evaluate the correlation of clinicopathological parameters 
with the expression of POLβ protein level. Wilcoxon signed 
test was used to compare POLβ protein level in the TDLUs 
and DCIS. Whilst Mann–Witney was used to compare POLβ 
protein level in pure DCIS and DCIS component coexist-
ent with IBC. To compare between DCIS component and 
invasive component in mixed cases, Wilcoxon Signed Ranks 
Test was used. Log rank and Kaplan Meier tests were used to 
perform the outcome analysis. p-value < 0.05 was considered 
significant.
Ethical approval was obtained by North West Manchester 
Ethics Committee under the title “Nottingham Health Sci-
ence Biobank (15/NW/0685)”.
The reporting recommendation for tumour markers prog-
nostic studies (REMARK) criteria was used in this study.
Results
POLβ protein expression
Stained full-face sections (n = 10) of DCIS and DCIS coex-
istent with invasive disease showed a homogenous distribu-
tion of POLβ expression which demonstrated the efficiency 
of using the TMA sections to evaluate POLβ expression. 
POLβ was expressed in nuclei of the TDLUs and tumour 
cells with variable intensities. Occasional weak to moderate 
staining in the cytoplasm of tumour cells was also noticed.
POLβ protein expression showed unimodal, non-par-
ametric distribution amongst the study cohort where the 
median H-score for the nuclear POLβ expression was 130 
(range 0–270) and for cytoplasmic expression was 60 (range 
0–240). Interestingly, these figures were similar to the cut-
off points identified by the X-tile software to stratify the 
cases according to outcome. Based on these cut-off points, 
high nuclear POLβ expression was observed in 388/465 
cases (83%) whilst low cytoplasmic POLβ expression was 
observed in 322/465 cases (69%).
POLβ expression in the mixed DCIS cohort
In the DCIS component in the DCIS-mixed cohort, positive 
nuclear staining was recognised in 189/198 cases (95%). 
Furthermore, positive cytoplasmic expression was rec-
ognised in 179/198 cases (90%). The median H-score for 
nuclear POLβ expression in the DCIS component was 100 
(range 0–220) and the median H-score for nuclear POLβ 
expression in the invasive component was 90 (range 0–180). 
For the cytoplasmic expression in the DCIS component, the 
median H-score was 60 (range 0–130). Low POLβ nuclear 
expression was observed in 46 out of 194 cases (76%), whilst 
low cytoplasmic expression was observed in 139/194 cases 
(72%) in the DCIS component.
Low nuclear expression was observed in 72 out of 222 
cases (32%) of invasive component of the mixed cohort. 
However, 139/194 cases (72%) representing low cytoplasmic 
expression were seen in the mixed DCIS coexistent with IBC 
of the mixed cohort (Fig. 1B–F).
POLβ protein expression levels were higher in the nuclei 
of TDLUs compared with the pure DCIS (p = 0.002). The 
level of nuclear POLβ expression in the pure DCIS was 
higher than the DCIS component coexistent with invasive 
cancer (p < 0.001). Moreover, the nuclear POLβ expression 
in the DCIS component coexistent with invasive in the mixed 
cohort was higher than the invasive component (p = 0.002). 
The nuclear intensity expression was greater in the TDLUs 
compare with the invasive component (p < 0.001) (Fig. 2).
The association between POLβ expression 
and clinicopathological parameters
Low nuclear POLβ protein expression in pure DCIS cohort 
was associated with aggressive clinicopathological param-
eters, including high nuclear grade (p = 0.001), comedo 
necrosis (p = 0.006), negative hormonal status (p < 0.001), 
positive HER2 status (p = 0.005) and with HER2 in molecu-
lar subtypes (p < 0.001) (Table 1). There was a significant 
association of low nuclear POLβ expression with large 
DCIS size (p = 0.018) and high proliferative index Ki-67 
(p = 0.008) (Supplementary Table S2). Low cytoplasmic 
POLβ expression was significantly associated with larger 
DCIS size (p = 0.017), diffused type of DCIS (p = 0.025) 
high nuclear grade (p = 0.015), PR negativity (p = 0.046), 
HER2 positivity (p = 0.007) and higher proliferation index 
(Ki67) (p = 0.021) (Table 2 and Supplementary Table S3).
Low POLβ nuclear expression in DCIS-mixed cohort was 
significantly associated with larger tumour size (p = 0.022), 
high nuclear grade (p = 0.025), comedo necrosis (p = 0.002), 
negative oestrogen receptor (p = 0.001) and with patients 
treated with mastectomy (p = 0.023). Results were con-
firmed by continuous data analysis (Table 3). Addition-
ally, low cytoplasmic POLβ expression was associated 
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with high nuclear grade (p = 0.034), presence of comedo 
necrosis (0.018) and negative oestrogen receptor (p = 0.018). 
Similar results were obtained by analysis of continuous data 
(Table 4).
POLβ nuclear/cytoplasmic (N/C) protein co-expression 
has been investigated in the DCIS cohort. 29% demonstrated 
high nuclear/high cytoplasmic expression (H.N/H.C), 54% 
showed H.N/L.C, 15% with L.N/L.C and 2% demonstrated 
L.N/H.C.
The L.N/L.C cluster was significantly associated 
with aggressive behaviour including high nuclear grade 
(p = 0.003), presence of comedo necrosis (p = 0.026), and 
larger size of DCIS (p = 0.010). However, the low protein 
expression of POLβ (L.N/L.C cluster) was observed more in 
the ER positive (p = 0.001) and HER2 negative (p = 0.004) 
tumours and in the luminal A molecular subgroup compared 
to other molecular subgroups (p < 0.001) (Table 5).
METABRIC cohort
Low POLβ mRNA expression was associated with young 
patient age (p = 0.001), premenopausal status (p = 0.015), 
high tumour grade (p < 0.001), negative hormonal status 
(ER&PR) (p < 0.001), positive HER2 status (p < 0.001) 
and basal-like breast cancer molecular subtype (p < 0.001) 
(Supplementary Table S4). Moreover, low POLβ mRNA 
expression was associated with shorter BCSS (p < 0.001, 
HR = 0.720, 95% CI 0.604–0.859) (Fig. 3A).
Association of POLβ and patient outcome
Low nuclear expression of POLβ in the DCIS was signifi-
cantly associated with poor outcome in the form of shorter 
LRFI for all recurrences (in situ recurrence and invasive 
recurrence) (p = 0.041. HR = 0.530, 95% CI 0.287–0.976) 
(Fig. 3B). A significant association was observed in patients 
who underwent BCS without adjuvant radiotherapy (RT) 
(p = 0.018. HR = 0.433, 95% CI 0.217–0.865), as well 
as in patients treated with BCS and received adjuvant 
radiotherapy (BCS + RT) (p = 0.041. HR = 0.528, 95% CI 
0.287–0.973) (Fig. 3C and D respectively).
Although POLβ cytoplasmic expression in pure DCIS did 
not show significant associations with patient outcome, com-
bined analysis of N/C expression revealed that L.N/L.C clus-
ter was associated with shorter LRFI (p = 0.022, HR = 2.234, 
95% CI 1.125–4.436) (Fig. 3E).
Low expression of POLβ nuclear protein in DCIS was 
an independent predictor of a poor outcome in DCIS when 
plotted against patient age, DCIS size, nuclear grade, 
radio-therapeutic treatment, HER2 status and proliferation 
index Ki67 (p = 0.031. HR = 0.490, 95% CI 0.256–0.936) 
(Table 6). Cytoplasmic POLβ expression but did not reveal 
any significant association as a predictor of patient outcome.
Functional studies
POLβ depletion and stemness phenotype in MCF10-DCIS 
cell line: The clinical data shown here suggest that downreg-
ulation of POLβ is associated with aggressive breast cancer 
pathogenesis. Therefore, we hypothesised that POLβ deple-
tion could be associated with increased stemness in DCIS 
Fig. 2  POL-β nuclear protein expression boxplot. POL-β nuclear protein expression boxplot showing the highest level of POL-β nuclear protein 
expression in the normal TDLUs, decreased to the lowest level in the IBC component of the mixed IBC series
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leading to aggressive phenotype. We showed that MCF10-
DCIS cells are non-invasive cell line, similar to MCF10A 
non-cancerous epithelial cells [32]. We performed POLβ 
knockdown by siRNA in MCF10-DCIS cells. We observed 
a robust knockdown of POLβ in our cells in day 3, 5 and 7, 
the most depleted level of POLβ protein level was observed 
in day 7 (Fig. 4A). We evaluated the expression of well iden-
tified stem cells markers in MCF10DCIS_POLβ_KD cells 
compared to controls. Interestingly, MCF10-DCIS_POLβ_
KD cells have a noticeable increase in C-MYC, OCT4, 
NANOG and SOX2 protein expression (Fig. 4B–E respec-
tively) suggesting that MCF10-DCIS_POLβ_KD acquired 
Table 1  Correlation between nuclear POL-β protein expression and 
clinicopathological parameters in pure DCIS cohort using categorical 
values
Significant p-values are in bold
No number, χ2 Chi square, POL-β DNA polymerase beta, DCIS 
ductal carcinoma in  situ, HER2 human epidermal growth factor 
receptor 2










  ≤ 50 20 (17.0) 96 (83.0) 116 (25.0) (0.052)
0.820  > 50 57 (16.0) 292 (84.0) 349 (75.0)
Sizea
  < 16 mm 21 (15.0) 124 (72.0) 145 (31.0) (1.239)
0.538 16–40 mm 30 (16.0) 154 (84.0 184 (40.0)
  > 40 mm 26 (19.0) 108 (81.0) 134 (29.0)
DCIS presentation
 Screening 34 (15.0) 192 (85.0) 226 (49.0) (0.730)
0.393 Symptomatic 43(18.0) 196 (82.0) 239 (51.0)
Nuclear grade
 Low 4 (7.0) 57 (93.0) 61 (13.0) (13.391)
0.001 Moderate 12 (10.0) 109 (90.0) 121 (26.0)
 High 61 (22.0) 222 (78.0) 283 (61.0)
Comedo necrosis
 No 17 (10.0) 150 (90.0) 167 (39.0) (7.676)
0.006 Yes 60 (20.0) 238 (80.0) 283 (61.0)
Oestrogen status
 Negative 31 (28.0) 81 (72.0) 112 (26.0) (13.414)
 < 0.001 Positive 41 (13.0) 281(87.0) 322 (74.0)
Progesterone status
 Negative 47 (26.0) 135 (74.0) 182 (41.0) (20.463)
 < 0.001 Positive 25 (10.0) 234 (90.0) 259 (59.0)
Her2 status
 Negative 43 (13.0) 281 (87.0) 324 (77.0) (8.068)
0.005 Positive 25 (25.0) 74 (75.0) 99 (23.0)
Proliferation index 
(Ki 67)
 Low (< 14%) 47 (15.0) 266 (85.0) 313 (77.0) (2.191)
0.139 High (≥ 14%) 20 (22.0) 73 (78.0) 93 (23.0)
Molecular classes
 Luminal A 21 (11.0) 170 (89.0) 191 (51.0) (18.926)
 < 0.001 Luminal B 11 (14.0) 69 (86.0) 80 (21.0)
 Her2 16 (37.0) 27 (63.0) 43 (11.0)
 Triple negative 12 (20.0) 84 (80.0) 60 (16.0)
Table 2  Correlation between cytoplasmic POL-β expression in DCIS 
with clinicopathological parameters in pure DCIS cohort using cat-
egorical values
Significant p-values are in bold
No number, χ2 Chi square, POL-β DNA polymerase beta, DCIS 
ductal carcinoma in  situ, HER2 Human epidermal growth factor 
receptor 2, LCIS lobular carcinoma in situ, BCS Breast conserving










  ≤ 50 86 (74.0) 30 (56.0) 116 (25.0) (1.736)
0.188  > 50 236 (6.0) 113 (32.0) 349 (75.0)
Sizea
  < 16 mm 88 (61.0) 57 (39.0) 145 (31.0) (8.169)
0.017 16–40 mm 133 (72.0) 51 (28.0) 184 (40.0)
  > 40 mm 101 (75.0) 33 (25.0) 134 (29.0)
DCIS presentation
 Screening 159 (70.0) 67 (30.0) 226 (49.0) (0.253)
0.615 Symptomatic 163 (68.0) 76 (32.0) 239 (51.0)
Nuclear grade
 Low 37 (61.0) 24 (39.0) 61 (13.0) (8.379)
0.015 Moderate 75 (62.0) 46 (38.0) 121 (26.0)
 High 210 (74.0) 73 (26.0) 283 (61.0)
Comedo necrosis
 No 109 (65.0) 58 (35.0) 167 (36.0) (1.936)
0.164 Yes 21 (71.0) 85 (29.0) 298 (64.0)
Oestrogen status
 Negative 84 (75.0) 28 (25.0) 112 (26.0) (3.013)
0.083 Positive 213 (66.0) 109 (34.0) 322 (74.0)
Progesterone status
 Negative 135 (74.0) 47 (26.0) 182 (41.0) (3.976)
0.046 Positive 169 (65.0) 90 (35.0) 259 (59.0)
Her2 status
 Negative 212 (65.0) 112 (35.0) 324 (77.0) (7.290)
0.007 Positive 79 (80.0) 20 (20.0) 99 (23.0)
Proliferation index 
(Ki 67)
 Low (< 14%) 210 (67.0) 103 (33.0) 313 (77.0) (5.310)
0.021 High (≥ 14%) 74 (80.0) 19 (20.0) 93 (23.0)
Molecular classes
 Luminal A 127 (66.0) 64 (34.0) 191 (51.0) (6.852)
0.077 Luminal B 55 (69.0) 25 (31.0) 80 (21.0)
 Her2 37 (86.0) 6 (14.0) 43 (12.0)
 Triple negative 39 (65.0) 21 (35.0) 60 (16.0)
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stemness phenotype associated cancerous self-renewal and 
increased cell division. However, MCF10-DCIS_POLβ_KD 
cells has a noticeable decrease in ALDH1 and no changes 
in N-cadherin and MMP-9 protein levels were observed in 
MCF10-DCIS_POLβ_KD cells (Fig. 4F–H respectively).
Discussion
Although breast cancer is a heterogeneous disease, there is 
a great similarity between DCIS and invasive carcinoma at 
histological and molecular levels. DNA damage repair is a 
complex mechanism that depends on the interaction between 
the various pathways to repair impaired DNA. The mecha-
nisms of DNA repair act as a barrier to maintain genetic 
stability as well as preventing cancer development. Follow-
ing DNA damage, one or more repair pathways are activated, 
such as BER. POLβ is one of the most important DNA poly-
merases in BER as it contributes to genome stability mainte-
nance [16, 33]. The role of the POLβ gene has been studied 
in many different tumours [16, 17, 27, 34–37]. In this study, 
POLβ low expression in the METABRIC cohort showed a 
significant association with an aggressive phenotype. This 
indicates the tumour suppressor role of POLβ in BC.
This study aimed to evaluate the expression of POLβ in 
a large DCIS cohort, as well as a DCIS-mixed cohort. The 
data provide evidence that POLβ might have a crucial role 
in DCIS genomic stability. Starcevic et al. [38] reported that 
one-third of total tumours examined expressed POLβ vari-
ant proteins and could induce genomic instability. Our data 
showed an association between low POLβ expression and 
aggressive DCIS phenotypes such as a high nuclear grade, 
which is consistent with Chantre-Justino et al. [33]. BER 
transcript profiling based on grade demonstrated differences 
in the molecular signature between the high and low-grade 
tumours, which is referred to as differential transcriptional 
regulation suggesting that BER dysregulation could promote 
carcinogenesis. POLβ gene has a misalignment-mediated 
mutator activity associated with aggressive mutator pheno-
type [38, 39]. It has been reported that cells with reduced 
expression of POLβ protein accumulate DNA damage and 
aggressive cancerous phenotype may be driven by muta-
tion and genomic instability that result from impaired BER 
[40]. Moreover, increased POLβ expression proved to be 
Table 3  Correlation between 
POL-β nuclear protein 
expression in DCIS component 
in mixed cohort
Significant p-values are in bold
No number, χ2 Chi square, POL-β DNA polymerase beta, DCIS ductal carcinoma in situ, BCS breast con-
serving, BCS breast conserving surgery
a Size: based on Van Nuys Prognostic Index (VNPI)









No. of cases Mean rank (χ2)
p-value
Age (years)
  ≤ 50 23 (25.0) 71 (75.0) 94 (48.0) 0.058 94 94.22 0.429
  > 50 23 (23.0) 77 (77.0) 100 (52.0) 0.810 100 100.58
Sizea
  < 16 mm 19 (22.0) 69 (78.0) 88 (45.0) 7.678 88 101.53 0.197
 16–40 mm 21 (22.0) 75 (78.0) 96 (50.0) 0.022 96 96.88
  > 40 mm 6 (60.0) 4 (40.0) 10 (5.0) 10 67.95
Nuclear grade
 Low 1 (10.0) 9 (90.0) 10 (5.0) 7.355 10 137.75  < 0.001
 Moderate 5 (11.0) 41 (89.0) 46 (24.0) 0.025 46 119.10
 High 40 (29.0) 98 (71.0) 138(71.0) 138 87.38
Comedo necrosis
 No 3 (7.0) 42 (93.0) 45 (23.0) 9.410 45 132.66  < 0.001
 Yes 43 (29.0) 106(71.0) 149(77.0) 0.002 149 86.88
Oestrogen status
 Negative 10 (53.0) 9 (47.0) 19 (10.0) 10.130 19 59.42 0.002
 Positive 35 (20.0) 139 (80.0) 174 (90.0) 0.001 174 101.10
Final operation
 Mastectomy 29 (31.0) 65 (69.0) 94 (48.0) 5.139 94 88.63 0.032
 BCS 17 (17.0) 83 (83.0) 100(52.0) 0.023 100 105.84
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resistant to DNA damage. These results suggest that POLβ 
can act as a caretaker gene where its absence associates with 
aggressive behaviour [41]. Our results showed that nega-
tive ER expression is associated with aggressive behaviour. 
Mobbley and Brueggemeier [42] reported that oestrogen 
evolves to carcinogenesis in the breast by creating a link 
that connects oestrogen-induced BC and an oxidative stress 
pathway. Moreover, there is a robust relationship between 
ER responsiveness and oxidative DNA damage that is sig-
nificantly elevated by approximately ten-fold in the invasive 
BC compared to normal breast tissue and about three-fold 
higher in positive ER than negative ER BC [43]. Bhat et al. 
[44] mentioned that oestrogen could promote carcinogenic-
ity by inducing oxidative stress. Interestingly, our results 
showed that low nuclear POLβ level was associated with ER 
negative cases which probably suggests that non oestrogen 
mediated oxidative stress pathways trigger DNA damage and 
particularly involve in DCIS.
Following our result, it has been found that amplified 
Her2 was associated significantly with aggressive behav-
iour and poor prognosis in breast cancer [25, 45]. Notably, 
expression of the HER2 level was different within various 
stages of BC progression. In general, Her2 in TDLUs was 
rarely detected in atypical ductal hyperplasia (ADH) but 
was amplified or overexpressed in high nuclear grade DCIS, 
especially in types of comedo necrosis and in a high nuclear 
grade of IBC. A loss of, or undetectable, Her2 protein levels 
in benign lesions suggests that its amplification or overex-
pression occurs in the transition from hyperplasia to DCIS, 
suggesting that overexpression is considered significant in 
early malignant progression [46]. It is therefore noticeable 
that the trend of decreasing POLβ occurs simultaneously 
with increasing HER2 expression when tumour aggressive-
ness increases. However, it is hard to conclude whether there 
is direct or indirect crosstalk between these two proteins as 
further molecular investigations required.
In this study, we explored the level of POLβ nuclear pro-
tein in a comparative cohort (mixed DCIS/IBC cohort). Our 
observations showed that a decreasing trend of POLβ levels 
was demonstrated starting from TDLUs, pure DCIS series, 
DCIS component coexisting with invasive disease and inva-
sive component which showed the lowest level of POLβ pro-
tein in the study cohort. This observation supports the notion 
of our hypothesis which states that the lack, or loss, of the 
POLβ protein associates with aggressive DCIS phenotype.
Table 4  Correlation between 
POLβ cytoplasmic protein 
expression in DCIS component 
in mixed cohort
Significant p-values are in bold. Mean rank operated by MannWhitey test and Kurskal test
POL-β DNA polymerase beta, DCIS ductal carcinoma in situ, Her2 human epidermal growth factor recep-
tor 2, BCS breast conserving
a Size: based on Van Nuys Prognostic Index (VNPI)









No. of cases Mean rank (χ2)
p value
Age (years)
  ≤ 50 69 (73.0) 25 (27.0) 94 (48.0) 0.058 94 93.61 0.346
  > 50 70 (70.0) 30 (30.0) 100(52.0) 0.810 100 101.16
Sizea
  < 16 mm 59 (67.0) 29 (33.0) 88 (45.0) 2.828 88 100.02 0.364
 16–40 mm 71 (74.0) 25 (26.0) 96 (50.0) 0.243 96 97.68
  > 40 mm 9 (90.0) 1 (10.0) 10 (5.0) 10 73.55
Nuclear grade
 Low 6 (60.0) 4 (40.0) 10 (5.0) 6.278 10 113.65 0.013
 Moderate 27 (27.0) 19 (41.0) 46 (24.0) 0.034 46 116.45
 High 106(77.0) 32 (23.0) 138(71.0) 138 90.01
Comedo necrosis
 No 26 (58.0) 19 (42.0) 45 (25.0) 5.550 45 117.66 0.006
 Yes 113(76.0) 36 (24.0) 149(75.0) 0.018 149 91.41
Oestrogen status
 Negative 18 (95.0) 1 (5.0) 19 (10.0) 5.583 19 81.00 0.186
 Positive 120(69.0) 54(31.0) 174(90.0) 0.018 174 98.75
Final operation
 Mastectomy 73 (78.0) 21 (22.0) 94 (48.0) 3.243 94 88.63 0.032
 BCS 66(66.0) 34 (34.0) 100(52.0) 0.072 100 105.84
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Low POLβ nuclear protein level showed significant asso-
ciation with shorter LRFI. A low level of nuclear POLβ was 
associated with recurrence in patients treated with adjuvant 
radiotherapy and in patients who did not receive radiothera-
peutics treatment after BCS. This is a clear signal suggesting 
that radio-therapeutic treatment does not provide any advan-
tages in DCIS patients with a low level of POLβ nuclear 
protein. More functional studies are required to understand 
the roles of POLβ in DCIS, especially with treatment. In 
clustering N/C survival, our data showed that the L.N/L.C 
cluster was the worst group in patient outcomes based on 
LRFI survival, this observation agrees with the aggressive 
attribute of low POLβ in DCIS.
Low POLβ nuclear protein was an independent predictor 
for all recurrences. Additionally, our preliminary study of 
POLβ depletion in MCF10-DCIS cells suggests that loss 
of POLβ could be associated with increased stemness phe-
notype in DCIS and hence progression to invasive breast 
cancer. POLβ knockdown cells had a significant increase in 
NANOG, SOX2, C-MYC and OCT4 which are well-known 
markers of cancer stem cells. However, overexpression of 
those markers was not associated with epithelial mesen-
chymal transition (EMT) as evidence by the no change in 
N-cadherin and MMP-9 which might have been more signif-
icant in a POLβ stable knock out cell line model. We antici-
pate that those changes happen over time DCIS. Therefore, 
Table 5  The correlation 
between Nuclear/Cytoplasmic 
(clustering) POLB expression 
in pure DCIS cohort with 
clinicopathological parameters
Significant p-values are in bold
POLβ DNA polymerase beta, DCIS ductai carcinoma in  situ, HER2 Enriched human epidermal growth 
factor receptor 2, H.N/H.C high nuclear/low cytoplasmic expression, H.N/L.C high nuclear/low cytoplas-















  ≤ 50 28 (21.0) 68 (27.0) 18 (26.0) 2 (25.0) 116 (25.0) (1.827)
0.585  > 50 107 (79.0) 185 (73.0) 51 (74.0) 6 (75.0) 349 (75.0)
DCIS size
  ≤ 20 mm 74 (56.0) 98 (39.0) 31 (45.0) 5 (62.0) 208 (45.0) (11.087)
0.010  > 20 mm 59 (44.0) 155 (61.0) 38 (55.0) 3 (38.0) 255 (55.0)
DCIS presentation
 Screening 63 (47.0) 129 (51.0) 30 (44.0) 4 (50.0) 226 (49.0) (1.510)
0.673 Symptomatic 72 (53.0) 124 (49.0) 39 (56.0) 4 (50.0) 239 (51.0)
Nuclear grade
 Low 24 (18.0) 33 (13.0) 4 (6.0) 0 (0.0) 61 (13.0) (18.978)
0.003 Moderate 44 (33.0) 65 (26.0) 10 (14.0) 2 (52.0) 121 (26.0)
 High 67 (50.0) 155 (61.0) 55 (80.0) 6 (75.0) 283 (61.0)
Comedo necrosis
 No 57 (42.0) 93 (37.0) 16 (23.0) 1 (13.0) 167 (36.0) (9.173)
0.026 Yes 78 (58.0) 160 (63.0) 53 (77.0) 7 (88.0) 298 (64.0)
Oestrogen receptor
 Negative 23 (18.0) 58 (25.0) 26 (41.0) 5 (62.0) 112 (26.0) (17.354)
0.001 Positive 106 (82.0) 175 (75.0) 38 (59.0) 3 (38.0) 322 (74.0)
Her2 status
 Negative 107(86.0) 174 (76.0) 38 (62.0) 5 (71.0) 324 (77.0) (12.831)
0.004 Positive 18 (14.0) 56 ( 24.0) 23 (38.0) 2 (29.0) 99 (23.0)
Proliferation index (Ki 67
 Low (≤ 14%) 98 (84.0) 168 (75.0) 42 (69.0) 5 (83.0) 313 (77.0) (6.455)
0.078 High (> 14%) 18 (16.0) 55 (25.0) 19 (31.0) 1 (17.0) 93 (23.0)
Molecular classes
 Luminal A 64 (58.0) 106 (52.0) 21 (39.0) 0 (0.0) 191 (51.0) (33.130)
 < 0.001 Luminal B 24 (22.0) 45 (22.0) 10 (18.0) 1 (17.0) 80 (21.0)
 Her2 5 (5.0) 22 (11.0) 15 (27.0) 1 (17.0) 43 (11.0)
 Triple negative 17 (16.0) 31 (15.0) 8 (15.0) 4 (66.0) 60 (16.0)
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more work is needed to identify the link between POLβ and 
stemness phenotype.
The study has some limitations it was carried out using 
TMA tissue preparations that may underestimate DCIS 
intratumour heterogeneity. However, full-face tissue sections 
revealed complete comparability of the heterogeneity of IHC 
expression. Moreover, the study included a small number of 
recurrence cases, limited data of patients with recurrence 
cases who received systemic therapy.
In conclusion, this study has shown the potential role of 
POLβ as a caretaker and tumour suppressor gene. The data 
provide evidence that loss or reduced expression of POLβ 
promotes tumour progression and is most probably associ-
ated with the aggressive behaviour of DCIS, which could 
progress to an invasive stage. Moreover, low POLβ protein 
level was also associated with a poor outcome within the 
DCIS. However, further molecular studies are required to 
further understand the underlying mechanisms.
Fig. 3  Association between POL-β expression and outcome. Kaplan–
Meier curves showing low expression of POL-β nuclear protein 
expression in tumour breast epithelial cells associated with A shorter 
LRFI in all recurrences of pure DCIS cohort. B In patients treated 
with BCS only. C In patients received adjuvant radiotherapy after 
BCS. D Shorter breast cancer specific survival of IBC in the META-
BRIC cohort. E, F Nuclear/cytoplasmic analysis revealed L.N/L.C 
cluster associated with shorter LRFI
Table 6  Cox regression analysis of POL-β nuclear protein expression 
in terms of predicting the outcome of local recurrence-free interval 
(LFRI) in DCIS patients of pure DCIS series treated by breast con-
serving surgery (BCS)
All recurrence /Multivariate survival analysis. Significant p-values 
are in bold
HR Hazard ratio, CI confidence interval, POL-β DNA polymerase 
beta, DCIS ductal carcinoma in situ, Her2 human epidermal growth 
factor receptor 2
Parameters p-value HR 95% CI
Lower Upper
POL-β Expression 0.031 0.490 0.256 0.936
Age 0.130 1.599 0.871 2.934
Nuclear Grade 0.678 1.096 0.710 1.694
Radiotherapy 0.893 0.942 0.392 2.262
Her2 Status 0.730 0.881 0.429 1.810
Proliferation index (Ki 67) 0.956 0.979 0.453 2.114
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